Liquidia Corporation Board of Directors

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Mr. Russell Schundler

Mr. Russell Schundler

General Counsel & Corporate Secretary

Mr. Scott Moomaw

Mr. Scott Moomaw

Chief Commercial Officer

Ms. Sarah Krepp SPHR

Ms. Sarah Krepp SPHR

Vice President of People & Culture

Mr. Jason Adair

Mr. Jason Adair

Chief Business Officer

Mr. Michael Hunter

Mr. Michael Hunter

Senior Vice President of Manufacturing Operations

Dr. Rajeev Saggar M.D.

Dr. Rajeev Saggar M.D.

Chief Medical Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.